Global Antisense Oligonucleotide Drugs(ASO Drugs) 麻豆原创 Growth 2025-2031

Publication ID:

LPI04255115

Publication Date:

April 23, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Antisense Oligonucleotide Drugs(ASO Drugs) market size is predicted to grow from US$ 4707 million in 2025 to US$ 15750 million in 2031; it is expected to grow at a CAGR of 22.3% from 2025 to 2031.
A class of molecular drugs that inhibit gene expression and regulate at the gene level through sequence specific binding with target gene DNA or mRNA
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The 鈥淎ntisense Oligonucleotide Drugs(ASO Drugs) Industry Forecast鈥� looks at past sales and reviews total world Antisense Oligonucleotide Drugs(ASO Drugs) sales in 2024, providing a comprehensive analysis by region and market sector of projected Antisense Oligonucleotide Drugs(ASO Drugs) sales for 2025 through 2031. With Antisense Oligonucleotide Drugs(ASO Drugs) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antisense Oligonucleotide Drugs(ASO Drugs) industry.
This Insight Report provides a comprehensive analysis of the global Antisense Oligonucleotide Drugs(ASO Drugs) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antisense Oligonucleotide Drugs(ASO Drugs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Antisense Oligonucleotide Drugs(ASO Drugs) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antisense Oligonucleotide Drugs(ASO Drugs) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antisense Oligonucleotide Drugs(ASO Drugs).
This report presents a comprehensive overview, market shares, and growth opportunities of Antisense Oligonucleotide Drugs(ASO Drugs) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Steric Hindrance
RNA Degradation
RNA Splicing Regulation
Segmentation by Application:
Hospital
Laboratory
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Lonis
Biogen
Sarepta
Novartis
Antisense Therapeutics
Akcea
Ruibo Bio
Inois
Therapeutics Inc.
Sanofi
Key Questions Addressed in this Report
What is the 10-year outlook for the global Antisense Oligonucleotide Drugs(ASO Drugs) market?
What factors are driving Antisense Oligonucleotide Drugs(ASO Drugs) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Antisense Oligonucleotide Drugs(ASO Drugs) market opportunities vary by end market size?
How does Antisense Oligonucleotide Drugs(ASO Drugs) break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Antisense Oligonucleotide Drugs(ASO Drugs) by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Antisense Oligonucleotide Drugs(ASO Drugs) by Country/Region, 2020, 2024 & 2031
2.2 Antisense Oligonucleotide Drugs(ASO Drugs) Segment by Type
2.2.1 Steric Hindrance
2.2.2 RNA Degradation
2.2.3 RNA Splicing Regulation
2.3 Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Type
2.3.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sale Price by Type (2020-2025)
2.4 Antisense Oligonucleotide Drugs(ASO Drugs) Segment by Application
2.4.1 Hospital
2.4.2 Laboratory
2.4.3 Other
2.5 Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Application
2.5.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Breakdown Data by Company
3.1.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Annual Sales by Company (2020-2025)
3.1.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Annual Revenue by Company (2020-2025)
3.2.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Company (2020-2025)
3.2.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Antisense Oligonucleotide Drugs(ASO Drugs) Sale Price by Company
3.4 Key Manufacturers Antisense Oligonucleotide Drugs(ASO Drugs) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Antisense Oligonucleotide Drugs(ASO Drugs) Product Location Distribution
3.4.2 Players Antisense Oligonucleotide Drugs(ASO Drugs) Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Antisense Oligonucleotide Drugs(ASO Drugs) by Geographic Region
4.1 World Historic Antisense Oligonucleotide Drugs(ASO Drugs) 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Antisense Oligonucleotide Drugs(ASO Drugs) 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Annual Sales by Country/Region (2020-2025)
4.2.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Annual Revenue by Country/Region (2020-2025)
4.3 Americas Antisense Oligonucleotide Drugs(ASO Drugs) Sales Growth
4.4 APAC Antisense Oligonucleotide Drugs(ASO Drugs) Sales Growth
4.5 Europe Antisense Oligonucleotide Drugs(ASO Drugs) Sales Growth
4.6 Middle East & Africa Antisense Oligonucleotide Drugs(ASO Drugs) Sales Growth
5 Americas
5.1 Americas Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Country
5.1.1 Americas Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Country (2020-2025)
5.1.2 Americas Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Country (2020-2025)
5.2 Americas Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Type (2020-2025)
5.3 Americas Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Region
6.1.1 APAC Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Region (2020-2025)
6.1.2 APAC Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Region (2020-2025)
6.2 APAC Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Type (2020-2025)
6.3 APAC Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Antisense Oligonucleotide Drugs(ASO Drugs) by Country
7.1.1 Europe Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Country (2020-2025)
7.1.2 Europe Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Country (2020-2025)
7.2 Europe Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Type (2020-2025)
7.3 Europe Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Antisense Oligonucleotide Drugs(ASO Drugs) by Country
8.1.1 Middle East & Africa Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Country (2020-2025)
8.1.2 Middle East & Africa Antisense Oligonucleotide Drugs(ASO Drugs) Revenue by Country (2020-2025)
8.2 Middle East & Africa Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Type (2020-2025)
8.3 Middle East & Africa Antisense Oligonucleotide Drugs(ASO Drugs) Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Antisense Oligonucleotide Drugs(ASO Drugs)
10.3 Manufacturing Process Analysis of Antisense Oligonucleotide Drugs(ASO Drugs)
10.4 Industry Chain Structure of Antisense Oligonucleotide Drugs(ASO Drugs)
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Antisense Oligonucleotide Drugs(ASO Drugs) Distributors
11.3 Antisense Oligonucleotide Drugs(ASO Drugs) Customer
12 World Forecast Review for Antisense Oligonucleotide Drugs(ASO Drugs) by Geographic Region
12.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) 麻豆原创 Size Forecast by Region
12.1.1 Global Antisense Oligonucleotide Drugs(ASO Drugs) Forecast by Region (2026-2031)
12.1.2 Global Antisense Oligonucleotide Drugs(ASO Drugs) Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Antisense Oligonucleotide Drugs(ASO Drugs) Forecast by Type (2026-2031)
12.7 Global Antisense Oligonucleotide Drugs(ASO Drugs) Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Lonis
13.1.1 Lonis Company Information
13.1.2 Lonis Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolios and Specifications
13.1.3 Lonis Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Lonis Main Business Overview
13.1.5 Lonis Latest Developments
13.2 Biogen
13.2.1 Biogen Company Information
13.2.2 Biogen Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolios and Specifications
13.2.3 Biogen Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Biogen Main Business Overview
13.2.5 Biogen Latest Developments
13.3 Sarepta
13.3.1 Sarepta Company Information
13.3.2 Sarepta Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolios and Specifications
13.3.3 Sarepta Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Sarepta Main Business Overview
13.3.5 Sarepta Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolios and Specifications
13.4.3 Novartis Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Antisense Therapeutics
13.5.1 Antisense Therapeutics Company Information
13.5.2 Antisense Therapeutics Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolios and Specifications
13.5.3 Antisense Therapeutics Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Antisense Therapeutics Main Business Overview
13.5.5 Antisense Therapeutics Latest Developments
13.6 Akcea
13.6.1 Akcea Company Information
13.6.2 Akcea Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolios and Specifications
13.6.3 Akcea Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Akcea Main Business Overview
13.6.5 Akcea Latest Developments
13.7 Ruibo Bio
13.7.1 Ruibo Bio Company Information
13.7.2 Ruibo Bio Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolios and Specifications
13.7.3 Ruibo Bio Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Ruibo Bio Main Business Overview
13.7.5 Ruibo Bio Latest Developments
13.8 Inois
13.8.1 Inois Company Information
13.8.2 Inois Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolios and Specifications
13.8.3 Inois Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Inois Main Business Overview
13.8.5 Inois Latest Developments
13.9 Therapeutics Inc.
13.9.1 Therapeutics Inc. Company Information
13.9.2 Therapeutics Inc. Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolios and Specifications
13.9.3 Therapeutics Inc. Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Therapeutics Inc. Main Business Overview
13.9.5 Therapeutics Inc. Latest Developments
13.10 Sanofi
13.10.1 Sanofi Company Information
13.10.2 Sanofi Antisense Oligonucleotide Drugs(ASO Drugs) Product Portfolios and Specifications
13.10.3 Sanofi Antisense Oligonucleotide Drugs(ASO Drugs) Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Sanofi Main Business Overview
13.10.5 Sanofi Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.